SCHEMBL731224

SCHEMBL731224

CCOc1c[c]ccc1-c1ccc(F)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.40
CYP2B6 P20813 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NR3C1 P04150 1/20 0.34
PDE10A Q9Y233 4/20 0.33
CYP2E1 P05181 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
SSTR5 P35346 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731879 0.82 CYP2A6 (0.43) CYP2A6MEN1KMT2A
SCHEMBL730591 0.77 ROCK2 (0.42)
SCHEMBL8088891 0.76 ALDH1A1 (0.35) CYP2A6CYP3A4KDM4EMEN1ALDH1A1
SCHEMBL6525290 0.75 ADRB2 (0.41) KDM4EALDH1A1MAPTHPGDMAPK1
SCHEMBL215578 0.75 ADORA3 (0.43) KDM4EALDH1A1MAPTHPGDHSD17B10
SCHEMBL732643 0.73 BRD4 (0.40) KDM4EPDE10AFGFR1
SCHEMBL160145 0.71 L3MBTL1 (0.46) CYP2C19KDM4EMEN1ALDH1A1POLB
SCHEMBL29196085 0.70 ALDH1A1 (0.44) CYP2C19KDM4EALDH1A1MAPTHPGD
SCHEMBL14702524 0.69 CYP3A4 (0.42) CYP2A6CYP2B6CYP3A4CYP2C19KDM4E
SCHEMBL2041601 0.69 CYP2A6 (0.48) CYP2A6L3MBTL1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 CYP2A6 191/4885CYP2B6 146/4885CYP3A4 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.